WO2023064717A3 - Antibodies for sars-cov-2 and uses thereof - Google Patents

Antibodies for sars-cov-2 and uses thereof Download PDF

Info

Publication number
WO2023064717A3
WO2023064717A3 PCT/US2022/077810 US2022077810W WO2023064717A3 WO 2023064717 A3 WO2023064717 A3 WO 2023064717A3 US 2022077810 W US2022077810 W US 2022077810W WO 2023064717 A3 WO2023064717 A3 WO 2023064717A3
Authority
WO
WIPO (PCT)
Prior art keywords
cov
sars
antibodies
methods
binding proteins
Prior art date
Application number
PCT/US2022/077810
Other languages
French (fr)
Other versions
WO2023064717A2 (en
Inventor
Christopher J. Emig
Rosanna CHAU
Payam Shahi
Kim-Xuan NGUYEN
YuShuan Lai
Robin Emig
John BEABER
Steven Henry
Marco MENA
Original Assignee
Augmenta Bioworks, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Augmenta Bioworks, Inc. filed Critical Augmenta Bioworks, Inc.
Publication of WO2023064717A2 publication Critical patent/WO2023064717A2/en
Publication of WO2023064717A3 publication Critical patent/WO2023064717A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The disclosure relates generally to the field of immune binding proteins and method for obtaining immune binding proteins from genomic or other sources. The disclosure also relates to anti-SARS-CoV-2 antibodies that have been obtained from subjects who became immune to this coronavirus, and to methods of using these anti-SARS-CoV-2 antibodies. Methods for neutralizing SARS-CoV-2 are disclosed, as well treatments for SARS-COV-2 using the anti-SARS-CoV-2 antibodies.
PCT/US2022/077810 2021-10-08 2022-10-07 Antibodies for sars-cov-2 and uses thereof WO2023064717A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163253677P 2021-10-08 2021-10-08
US63/253,677 2021-10-08

Publications (2)

Publication Number Publication Date
WO2023064717A2 WO2023064717A2 (en) 2023-04-20
WO2023064717A3 true WO2023064717A3 (en) 2023-09-14

Family

ID=85988855

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/077810 WO2023064717A2 (en) 2021-10-08 2022-10-07 Antibodies for sars-cov-2 and uses thereof

Country Status (1)

Country Link
WO (1) WO2023064717A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021045836A1 (en) * 2020-04-02 2021-03-11 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2021183947A1 (en) * 2020-03-12 2021-09-16 University Of Pittsburgh - Of The Commonwealth System Of Higher Education MOLECULES THAT BIND TO SARS-CoV-2
US20210292392A1 (en) * 2020-03-20 2021-09-23 Tsb Therapeutics (Beijing) Co., Ltd. Anti-sars-cov-2 antibodies and uses thereof
WO2021195326A1 (en) * 2020-03-26 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
US20210347860A1 (en) * 2020-05-11 2021-11-11 Augmenta Bioworks, Inc. Antibodies for sars-cov-2 and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021183947A1 (en) * 2020-03-12 2021-09-16 University Of Pittsburgh - Of The Commonwealth System Of Higher Education MOLECULES THAT BIND TO SARS-CoV-2
US20210292392A1 (en) * 2020-03-20 2021-09-23 Tsb Therapeutics (Beijing) Co., Ltd. Anti-sars-cov-2 antibodies and uses thereof
WO2021195326A1 (en) * 2020-03-26 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
WO2021045836A1 (en) * 2020-04-02 2021-03-11 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
US20210347860A1 (en) * 2020-05-11 2021-11-11 Augmenta Bioworks, Inc. Antibodies for sars-cov-2 and uses thereof

Also Published As

Publication number Publication date
WO2023064717A2 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
WO2021231237A3 (en) Antibodies for sars-cov-2 and uses thereof
WO2018237148A8 (en) Multispecific antibodies that target hiv gp120 and cd3
MX2020009366A (en) Anti-cd73 antibodies and uses thereof.
MY194642A (en) Antibodies binding to cd3
CA3156451A1 (en) Antibodies having specificity for nectin-4 and uses thereof
WO2019224718A3 (en) Psma binding agents and uses thereof
JOP20200309A1 (en) Il-11 antibodies
EP4219724A3 (en) Compositions and methods for treating non-age-associated hearing impairment in a human subject
PH12020552229A1 (en) Il-11ra antibodies
MY194997A (en) Anti-ccr7 antibody drug conjugates
MX2023004869A (en) Antibodies against sars-cov-2 and uses thereof.
WO2019217145A8 (en) Anti-dll3 antibodies and uses thereof
MX2022002682A (en) Anti-cd73 antibodies.
CR20210622A (en) Multispecific heavy chain antibodies binding to cd22 and cd3
MX2021009079A (en) Methods of treating multiple myeloma.
MX2023004054A (en) Anti-dectin-1 antibodies and methods of use thereof.
CR20220628A (en) Antibodies binding to cd3
WO2022082073A3 (en) Compositions and methods for muc18 targeting
MX2024002238A (en) Anti-ccr8 antibodies and uses thereof.
WO2022034524A3 (en) Antibodies against ilt2 and use thereof
CR20220505A (en) Anti-phf-tau antibodies and uses thereof
PH12020500662A1 (en) Anti-pfrh5 antibodies and antigen-binding fragments thereof
ZA202305072B (en) Cd1a antibodies and uses thereof
WO2020180712A8 (en) Anti-tnfr2 antibodies and uses thereof
MX2022015966A (en) Antibodies and methods for treating claudin-associated diseases.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22881929

Country of ref document: EP

Kind code of ref document: A2